Unlike the majority of biotech players, Kazia Therapeutics has emphasised diversity in its clinical trials, so as to look at the potential of its lead drug paxalisib in a range of different treatment areas.

Kazia Therapeutics CEO James Garner joins Small Caps to discuss the company’s ongoing development of its lead drug paxalisib, which recently generated positive interim data in a phase one clinical trial for treating brain metastases.

Interim data from the study reveals a complete or partial response in all evaluable trial participants for a disease with a poor prognosis and limited current options.